Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

994 Pages (Click to Jump) V   1 2 3 4 > »    
 
  
Reply to this topic

BLT, BENITEC BIOPHARMA LIMITED
plastic
post Posted: Yesterday, 07:23 PM
  Quote Post


Posts: 10,910
Thanks: 315


These are comments from the ex-CEO of Silence Therapeutics, another gene silencing company based in England. Before they were called Silence they were called SR Pharma. They conducted trials which were a terrific failure, with Daiichi Sangyo out of Japan. We have seen much from Takeda in the gene silencing space but none from Daiichi. That the ex-CEO of Silence is saying this, perhaps he knows a little something and Daiichi is about to play their hand in unison with its partners.

QUOTE
Ali Mortazavi@AAMortazavi·May 5Bios... need a takeover. #xbi

QUOTE

Ali Mortazavi@AAMortazaviI think this has been the news that the market has "known about". Buy the news opportunity coming up over next few days. #xbi

QUOTE
Ali Mortazavi@AAMortazavi·18hMy #xbi nausea indicator is getting high. Time to buy.




--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: May 4 2021, 04:02 AM
  Quote Post


Posts: 10,910
Thanks: 315


Here are the details of the cap. raise. Price is down again today. Lincoln Park are known shorters. Wouldn't be surprised if this falls foul of the minimum price and market cap requirements of the NASDAQ in the end.

https://finance.yahoo.com/news/benitec-biop...-015500360.html

QUOTE
HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 3,036,366 shares of common stock of the Company at a price to the public of $4.25 per share, less underwriting discounts and commissions. The Company has also granted the underwriter a 30-day option to purchase up to an additional 455,454 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about April 30, 2021, subject to satisfaction of customary closing conditions.




--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: May 1 2021, 08:34 AM
  Quote Post


Posts: 10,910
Thanks: 315


In Reply To: plastic's post @ Apr 13 2021, 02:04 PM

QUOTE
School holidays this weekend. As my broker mate once said to me, forget about school holidays. Nothing ever happens during school holidays.


They finish this weekend. So far, he is right on the money. But that's not hard when nothing happens at all for ever!




--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: Apr 30 2021, 12:00 PM
  Quote Post


Posts: 10,910
Thanks: 315


This explains a few things of whats going on recently. Lincoln Park were the buyers. Not a good sign.

All it really says is, business as usual.


https://www.sec.gov/Archives/edgar/data/159...526d1_sc13g.htm


QUOTE
On April 27, 2021, Benitec Biopharma Inc. (the “Company”) entered into an amended and restated underwriting agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC (the “Underwriter”), relating to the sale of 3,036,066 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), in an upsized, firm-commitment public offering pursuant to the Company’s effective registration statement on Form S-3 (File No. 333-253259) and related prospectus and prospectus supplement, in each case filed with the Securities and Exchange Commission (the “Offering”). The public offering price is $4.25 per share, less underwriting discounts and commissions. In addition, the Company granted the Underwriter an option to purchase, for a period of 30 days from the date of the Underwriting Agreement, up to an additional 455,454 shares of Common Stock at the same public offering price.

In connection with the Offering, the Company agreed to pay the Underwriter an underwriting discount equal to 8.0% of the gross proceeds of the offering and a management fee equal to 1.0% of the gross proceeds of the offering. The Company has also agreed to pay the Underwriter (a) $50,000 for non-accountable expenses, (b) up to $100,000 for reasonable, documented fees and expenses of legal counsel and other reasonable out-of-pocket expenses and © clearing and settlement fees of $15,950.

The Company estimates that the net proceeds from the Offering will be approximately $11.3 million, or approximately $13.1 million if the Underwriter exercises in full its option to purchase additional shares of Common Stock, in each case after deducting underwriting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds from the Offering for the continued advancement of development activities for its product pipeline, general corporate purposes, and strategic growth opportunities. The Offering is expected to close on or about April 30, 2021, subject to satisfaction of customary closing conditions.

The Underwriting Agreement contains representations, warranties, indemnification and other provisions customary for transactions of this nature. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. Pursuant to the Underwriting Agreement, the Company and its directors and officers agreed, for a period of 90 days, subject to certain exceptions, not to offer, sell, pledge or otherwise dispose of the common stock and other Company securities, without the prior written consent of the Underwriter.

The foregoing summary of the Underwriting Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the Underwriting Agreement, which is attached hereto as Exhibit 1.1 and incorporated herein by reference.

A copy of the opinion of Proskauer Rose LLP as to the legality of the shares of Common Stock to be issued in the Offering and related consent is attached hereto as Exhibit 5.1 to this Current Report on Form 8-K.

Item 1.01
Entry into a Material Definitive Agreement.







--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: Apr 29 2021, 01:03 AM
  Quote Post


Posts: 10,910
Thanks: 315


Anarchy in the USA. BNTC down 25% on volume! 44% in two days!!

Is there trial data due? Nant in trouble?

No idea what it is but at all time lows this can't be a bad buy atm.



--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: Apr 28 2021, 06:58 AM
  Quote Post


Posts: 10,910
Thanks: 315


Wow. Down 18% for the day. 16% after hours. Meantime Novavax is on a screamer. Might be India's saviour.

A lot of volatility going on.




--------------------
What did Uncle Mel do to us?
 


plastic
post Posted: Apr 24 2021, 07:41 AM
  Quote Post


Posts: 10,910
Thanks: 315


Plus 20% in the last couple of days. Better buy some quick.



--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: Apr 22 2021, 06:42 AM
  Quote Post


Posts: 10,910
Thanks: 315


Volumes are still light but there was a big jump in price and volume relative to the rest of the day right at the end of trading today.

Prices are at all time lows which must be about a thousandth of a cent for any long term holder who has been in since the start. Quite disgusting really.

Funnily enough I now rate it as a buy. Not for any fundamental reason but because I subscribe to the Dogs of the Dow theory.




--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: Apr 17 2021, 03:38 PM
  Quote Post


Posts: 10,910
Thanks: 315


Reading about the clots from the vaccines I am reminded about the kid who died from the Nucleonics therapy. Apparently, that set the industry back about ten years. Now, it appears if you die while taking an experimental gene therapeutic, it doesn't make any difference. The politicians are just going to endorse whatever it is they are told to by their power brokers and the regulators will just go along with it.

Surely, this situation cannot continue. AZ and JNJ, both companies who worked with BLT's ddRNAi, have to pull their vaccines.




--------------------
What did Uncle Mel do to us?
 
plastic
post Posted: Apr 16 2021, 06:44 AM
  Quote Post


Posts: 10,910
Thanks: 315


For 12 months BNTC is down 14%. For the last 6 months its up 57%.

Remember the old story: It's not timing the market but time in the market which makes the money.

If this is true, then there's huge upside coming because there are a lot of people who are bitter about the losses they have incurred from holding this dog.

The perennial freeloaders in the boardroom must be very concerned about it all.

Price down 10% again today.



--------------------
What did Uncle Mel do to us?
 
 


994 Pages (Click to Jump) V   1 2 3 4 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING